There’s a growing body of evidence demonstrating technology-led digital transformations are overpromising and under-delivering returns on investment for
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) (“Valeant” or the “Company”) has announced that, pursuant to a recommendation by its Patient Access and Pricing Committee, the company will make